An significant RNAi Therapeutics Market research report has been created using a thorough and competent investigation, taking into account the needs of the customer. This outstanding market study assesses the market's current condition, market share and size, revenue from product sales, and necessary modifications that must be made to future items. With the newest technologies, creative programs, and new abilities, it makes the process of gaining insightful market knowledge easier and will undoubtedly help businesses achieve their objectives. A thorough analysis of the product specs, revenue, cost, pricing, gross capacity, and production is also included in the first-rate RNAi Therapeutics Market research.
Explore Further Details about This Research RNAi Therapeutics Market Report https://www.databridgemarketresearch.com/reports/global-rnai-therapeutics-market
According to the World Health Organization estimates that cancer caused 9.6 million deaths in 2018 and is the second-highest cause of death worldwide. About 1 in 6 fatalities worldwide are caused by cancer. Over the following two decades, there will likely be a 70 percent increase in new cases. Additionally, recent developments have made it possible to overcome this barrier and facilitate the clinical use of RNAi-based therapeutics for cancer treatment.
Data Bridge Market Research analyses that the RNAi therapeutics market which was USD 807.99 million in 2022, would rocket up to USD 1645.76 million by 2030, and is expected to undergo a CAGR of 9.3% during the forecast period 2023 to 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
A brand-new class of drugs based on ribonucleic acid is known as RNA therapies (RNA). Target mRNA molecules are neutralized during the biological process known as RNA interference, and RNA molecules are then shown to impede gene expression or translation. Additionally, RNA interference (RNAi) is a group of short RNA-directed processes that inhibits the expression of genes in a sequentially-specific manner.
Drivers
Rising cases of chronic diseases
The rising rates of chronic diseases like cancer, cardiovascular conditions, and others will accelerate market expansion. The RNAi therapeutics market will be further fuelled by additional factors such as rising RNAi therapeutic approvals, advancements in the healthcare sector, rising R&D expenditures, and rising pharmaceutical company collaborations during the forecast period of 2023 to 2030.
Increasing collaborative activities
The increasing collaboration activities between drug distribution companies and contract research organizations (CROs) contribute to the growth of the RNAi therapeutics market. Arrowhead Pharmaceuticals Inc and Horizon Therapeutics plc announced a global collaboration and licence agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout, on June 21, 2021. This collaboration with Horizon also represents an expansion of Arrowhead Pharmaceuticals' rapidly growing pipeline of investigational RNAi therapeutics based on the company's proprietary Targeted RNAi Molecule (TRiMTM) platform." In January 2016, Ionis Pharmaceuticals (previously Isis Pharmaceuticals) began a Phase-I study of ISIS-HBV-L Rx in collaboration with GSK Pharmaceuticals. This acquisition aims to treat Hepatitis B viral infection.
Recent Development
On February 26, 2020, The Brazilian Health Regulatory Agency (ANVISA) approved ONPATTRO for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adults, according to a prominent company's announcement.
In June 2020, OliX Pharmaceuticals and LGC Biosarch Technology agreed to quicken the manufacturing of asymmetric siRNA for treating wet macular degeneration and subretinal fibrosis.
Global RNAi Therapeutics Market Scope
The RNAi therapeutics market is segmented on the basis of molecule type, application, route of administration and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Molecule Type
Small Interfering RNAS
Microrna
Application
Genetic Disorder
Oncology
Neurodegenerative Disorder
Cardiovascular Disorder
Respiratory Disorder
Infectious Disease
Renal Disease
Other
 Route of Administration
Intradermal Injections
Pulmonary Delivery
Intravenous Injections
Intraperitoneal Injections
Others
End-User
Diagnostic Laboratories
Research and Academic Laboratories
Hospitals
Some of the major players operating in the RNAi therapeutics market are:
Quark Software Inc. (U.S.)
Hoffmann-La Roche Ltd. (Switzerland)
Rexahn Pharmaceuticals, Inc. (U.S.)
Silence Therapeutics (U.K.)
Arbutus Biopharma (U.S.)
Benitec Biopharma (Australia)
GSK plc (U.K.)
OLIX PHARMACEUTICALS, INC. (South Korea)
Sanofi (France)
Alnylam Pharmaceuticals, Inc. (U.S.)
Moderna Inc. (U.S.)
Ionis Pharmaceuticals (U.S.)
Key questions answered in the RNAi Therapeutics Market are: 
What is RNAi Therapeutics Market?
What was the RNAi Therapeutics Market size in 2022?
What are the different segments of the RNAi Therapeutics Market?
What growth strategies are the players considering to increase their presence in RNAi Therapeutics Market?
What are the upcoming industry applications and trends for the RNAi Therapeutics Market?
What are the recent industry trends that can be implemented to generate additional revenue streams for the RNAi Therapeutics Market?
What major challenges could the RNAi Therapeutics Market face in the future?
What segments are covered in the RNAi Therapeutics Market?
Who are the leading companies and what are their portfolios in RNAi Therapeutics Market?
What segments are covered in the RNAi Therapeutics Market?
Who are the key players in the RNAi Therapeutics Market?
Browse Related Reports:
Surgical Light Source Market Size and Forecasts, Share and Trends
https://www.databridgemarketresearch.com/reports/global-surgical-light-source-market
Video Microscopes Market Size, Industry Share, Forecast
https://www.databridgemarketresearch.com/reports/global-video-microscopes-market
Needle-Free IV Connectors Market | Size,Share, Growth
https://www.databridgemarketresearch.com/reports/global-needle-free-iv-connectors-market
Infertility Treatment Devices and Equipment Market Size, Trends & Growth Analysis
https://www.databridgemarketresearch.com/reports/global-infertility-treatment-devices-and-equipment-market
Orthodontic Bands Market- Global Industry Analysis and Forecast
https://www.databridgemarketresearch.com/reports/global-orthodontic-bands-market
Panniculitis Market Value | Size,Trends,Forecast|
https://www.databridgemarketresearch.com/reports/global-panniculitis-market
Pressure Ulcer Treatment Market Demand,Size , Share, Industry
https://www.databridgemarketresearch.com/reports/global-pressure-ulcer-treatment-market
Retinal Detachment Treatment Market Size, Analysis and Forecast
https://www.databridgemarketresearch.com/reports/global-retinal-detachment-treatment-market
Uterine Fibroids Drug Market Size, Share, Trends & Forecast
https://www.databridgemarketresearch.com/reports/global-uterine-fibroids-drug-market
Gitelman Syndrome (GS) Treatment Market Size And Share Analysis Report,
https://www.databridgemarketresearch.com/reports/global-gitelman-syndrome-gs-treatment-market
About Data Bridge Market Research:
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email – corporatesales@databridgemarketresearch.com

Items